Compare Las Vegas Sands Corp. (LVS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs BIO-TECHNE Corp — how do they compare? Las Vegas Sands Corp. trades at $45.98 (market cap $29.44B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Las Vegas Sands Corp. is far larger — about 2.6× BIO-TECHNE Corp's market cap, and Las Vegas Sands Corp. pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| LVS | TECH | |
|---|---|---|
Market Cap | $29.44B | $11.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $72.29 |
52-Week Low | $44.78 | $43.31 |
Enterprise Value | $41.33B | $11.32B |
Dividend Yield | 2.64% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $45.77, down 0.74% on the day, with a bearish technical signal and recent Q2 2026 earnings miss. The company shows strong fundamentals with revenue growth to $13.02B in 2025, a net income margin of 12.59%, and robust cash flow from operations of $3.02B. Analyst consensus remains bullish with a $60.75 price target and 59% buy ratings, supported by positive corporate news on ESG achievements and community initiatives.
The outlook for LVS is mixed; strong profitability and analyst optimism contrast with technical bearishness and high debt levels. Upside potential exists if earnings rebound, but risks include competitive pressures and macroeconomic sensitivity. The stock's current valuation at a P/E of 17.74 offers a reasonable entry if operational execution improves.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
